Search research articles
Contact Us
Filters
Showing results (121-130 of 137) with videos related to
Page
of 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2004
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy
Mory Nouriani, Afshin Bahador, Jonathan S Berek, et al.
Gynecologic Oncology
|
March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2025
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer
Sharon H Nahm, Belinda E Kiely, Rachel L O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Josep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.
The Lancet. Oncology
|
April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Yeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Gynecologic Oncology
|
June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer
Rachel Campbell, Daniel S J Costa, Martin R Stockler, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics
|
January 19, 2019
Revised FIGO staging for carcinoma of the cervix uteri
Neerja Bhatla, Jonathan S Berek, Mauricio Cuello Fredes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2013
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study
Paul Sabbatini, Philipp Harter, Giovanni Scambia, et al.
Nature Reviews. Cancer
|
September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 137) with videos related to
Sort By:
Page
of 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2004
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy
Mory Nouriani, Afshin Bahador, Jonathan S Berek, et al.
Gynecologic Oncology
|
March 26, 2025
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2025
Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer
Sharon H Nahm, Belinda E Kiely, Rachel L O'Connell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Josep M Del Campo, Ursula A Matulonis, Susanne Malander, et al.
The Lancet. Oncology
|
April 6, 2019
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Kathleen N Moore, Angeles Alvarez Secord, Melissa A Geller, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 28, 2022
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
Yeh Chen Lee, Madeleine T King, Rachel L O'Connell, et al.
Gynecologic Oncology
|
June 19, 2022
Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer
Rachel Campbell, Daniel S J Costa, Martin R Stockler, et al.
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics
|
January 19, 2019
Revised FIGO staging for carcinoma of the cervix uteri
Neerja Bhatla, Jonathan S Berek, Mauricio Cuello Fredes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 13, 2013
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study
Paul Sabbatini, Philipp Harter, Giovanni Scambia, et al.
Nature Reviews. Cancer
|
September 24, 2011
Rethinking ovarian cancer: recommendations for improving outcomes
Sebastian Vaughan, Jermaine I Coward, Robert C Bast, et al.
Page
of 14